Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.59 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.54 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.53 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.48 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.48 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.48 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.48 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.48 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111607 | 0.98 | GFER (0.62) | MAOBHTR2AGFERMAOACA2 | |
| Iodide SCHEMBL31425562 | 0.95 | HTR2A (0.59) | MAOBHTR2AGFERMAOACA2 | |
| SCHEMBL22346191 | 0.93 | HTR2A (0.69) | MAOBHTR2AGFERCA2SMN1; SMN2 | |
| SCHEMBL3432822 | 0.93 | HTR2A (0.57) | MAOBHTR2AGFERMAOACA2 | |
| Hydrochloric Acid SCHEMBL7959598 | 0.91 | HTR2A (0.73) | MAOBHTR2AGFERCA2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7960660 | 0.91 | HTR2A (0.73) | MAOBHTR2AGFERCA2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL38666204 | 0.91 | HTR2A (0.73) | MAOBHTR2AGFERCA2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7937804 | 0.91 | HTR2A (0.73) | MAOBHTR2AGFERCA2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9330758 | 0.91 | HTR2A (0.73) | MAOBHTR2AGFERCA2SMN1; SMN2 | |
| SCHEMBL8771395 | 0.91 | ALDH1A1 (0.61) | MAOBHTR2AGFERMAOACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100422140-C | 3-benzyloxy-4-butylaniline hydrochloride preparation method | UNIV ZHEJIANG (CN) | 2008-10-01 | — | — | CN | claimed |
| CN-1733703-A | 3-benzyloxy-4-butylaniline hydrochloride preparation method | UNIV ZHEJIANG (CN) | 2006-02-15 | — | — | CN | claimed |
| EP-1964860-B1 | ETHYLENE POLYMER, CATALYST FOR PRODUCTION OF ETHYLENE POLYMER, AND PROCESS FOR PRODUCTION OF ETHYLENE POLYMER | TOSOH CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-8841396-B2 | Ethylene-α-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20130324691-A1 | Ethylene-a-Olefin Copolymer and Article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| EP-2650286-A1 | Quinazoline derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8404698-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130005930-A1 | ETHYLENE-alpha-OLEFIN COPOLYMER AND MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| CN-1956966-B | Quinazoline derivatives and their therapeutic use | REXAHN CORP | 2012-04-18 | — | — | CN | disclosed |
| US-7838611-B2 | Ethylene polymer, catalyst for ethylene polymer production, and method for producing ethylene polymer | TOSOH CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090137755-A1 | ETHYLENE POLYMER, CATALYST FOR ETHYLENE POLYMER PRODUCTION, AND METHOD FOR PRODUCING ETHYLENE POLYMER | TOSOH CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| CN-1956966-A | Quinazoline derivatives and their therapeutic use | REXAHAN CORP (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1720841-A2 | QUINAZOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080352-A2 | QUINAZOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187231-A1 | Quinazoline derivatives and therapeutic use thereof | REXAHAN CORPORATION (US) | 2005-08-25 | — | — | US | disclosed |
| EP-0849292-B1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORP (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-6110858-A | AN OLEFIN POLYMERIZATION CATALYST CONSISTS OF A TRANSITION METAL COMPOUND, A MODIFIED CLAY COMPOUND CONTAINING CLAY MINERAL AND AN AMINE COMPOUND AND AN ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0849292-A1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORPORATION (JP) | 1998-06-24 | — | — | EP | disclosed |
| CN-1014060-B | METHOD FOR PREPARAING ORTHO-AZONAPHTHALENE COMPOUND | IMP CHEMICAL IND PAN AMERICAL (US) | 1991-09-25 | — | — | CN | disclosed |
| CN-86104358-A | The preparation method of cinnoline compound | — | 1987-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187231-A1 | Quinazoline derivatives and therapeutic use thereof | ABL1, NQO2, NRAS | MAOB 2084/4885HTR2A 3321/4885MAOA 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.